The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISLB 2021 | Future directions for lung cancer research
Amy Moore, PhD, LUNGevity Foundation, San Carlos, CA, discusses future directions for lung cancer research and highlights the importance of biomarker testing. Biomarker testing, such as next-generation sequencing, has the potential to capture a wide range of biomarkers, which then provides clinicians and patients with more information to allow them to make the best treatment decisions. Dr Moore also emphasises the importance of education initiatives and policy work for improving the future of lung cancer treatment and research. This interview took place at the International Society of Liquid Biopsy (ISLB) 2021 Virtual Meeting.
